Funding Partnerships FAST is the leading non-profit funder of Angelman syndrome research with a multi-million dollar revenue range, presenting a strong opportunity for industry and academic partnerships, grants collaboration, sponsored research, and translational programs aligned with their mission.

Clinical & Translational Their focus on moving research from bench to bedside and funding at multiple stages indicates readiness to engage in translational research collaborations, clinical trial support, and early-phase studies with partners possessing relevant assets.

Strategic Collaborations Past partnerships with institutions like Rush University Medical Center and biotech companies demonstrate a willingness to collaborate across academia and industry to advance therapies, creating avenues for co-development, joint ventures, and milestone-based funding.

Rapid Grant Cycles Rolling grant applications and a fast-moving funding approach suggest a receptive channel for sponsorships, grant-backed programs, and research initiatives that align with FAST’s prioritization and speed-to-impact goals.

Awareness & Advocacy As the largest non-governmental funder in this space, FAST has substantial patient advocacy reach and brand credibility, enabling opportunities in awareness campaigns, educational partnerships, and community engagement initiatives that can drive program adoption and influence market access for emerging therapies.